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The autistic spectrum disorders (ASD) are complex
developmental disorders that manifest during childhood.
By deﬁnition, children with ASD are characterized by
qualitative impairments in social interaction, deﬁcits in
verbal and non-verbal communication, and with restricted
repetitive and stereotyped patterns of behavior and
interests (American Psychiatric Association, 1994). ASD
describes a range of conditions including autism and
Asperger’s syndrome that fall within the umbrella term of
pervasive developmental disorders (PDD). The prevalence
of ASD has increased substantially over the last decade
rising from 5 to 60/10,000 (Fombonne, 1999; Bertrand
et al., 2001; Chakrabarti and Fombonne, 2001; Fombonne
et al., 2001; Wing and Potter, 2002). The male to female
ratio in autism are also skewed with a three- to four-fold
increased incidence in boys. In the majority of cases the
cause of ASD are unknown, although strong genetic links
have been shown for cases with tuberous sclerosis,
neuroﬁbromatosis, chromosomal abnormalities and
fragile X. In addition, environmental factors have been
implicated for prenatal rubella infection, anticonvulsants
and antiemetics taken during pregnancy, perinatal
hypoxia, post-natal infections such as encephalitis and in
metabolic disorders such as phenylketonuria (Fombonne
et al., 2001; Baird et al., 2003). Evidence for the
contributing role of genetic factors in ASD have also come
from monozygotic twin and family studies, with
concordance rates for broad spectrum ASD of 90% and
a familial risk of 5–10 times higher than the general
population, respectively (Bailey et al., 1995; Szatmari,
1999; Rutter, 2000). However, within the general
population there appears to be no bias or selective
pressure against ASD traits, where arguably from the
evolutionary viewpoint due to impairments in social
interactions and in some cases lifelong dependency, one
would anticipate selective pressure would exist. As such,
it has been suggested through genomic screens, that in
autism there are multiple weak gene interactions.
Indeed, many candidate genes that determine disease
susceptibility, or severity, or disease course, have been
implicated and studied in autism. There exists a great
variabilityingeneexpression(Szatmari,1999;Rischetal.,
1999; Rutter, 2000), with the most likely genetic models
predicting multiple gene interactions of up to 15 or more
with low individual contributions. However, unequivocal
evidence for a genetic association with ASD has so far
not been established. Moreover, with the increased
prevalence of autism the inﬂuence of a deﬁnitive set of
genetic determinants has become more difﬁcult to
determine. The lack of association between ASD and
social class, immigrant status and geographical location
may suggest that a biological i.e. not solely genetic cause,
plays a leading role in the etiology of autism. Furthermore,
features such as epilepsy, clear clinical regression of
development, mental retardation, persistent neurological
signs such as primitive reﬂexes (Volkmar et al., 2003) and
gastrointestinal symptoms occur in some but not in all
cases. Thus there may exist subsets of ASD patients, with
separate multiple etiologies that affect biological and
psychological functioning, that manifest with differing
clinical phenotypes.
There is a growing awareness of an immunological
involvement in children with ASD. Systemic immuno-
logic aberrations in ASD have been linked with both
autoimmunity, describing antibodies reactive for CNS
proteins with the potential for neuronal tissue destruction,
and secondly, with dysfunctional immunity such as
abnormalities or deﬁcits of function in immune cell
subsets, leading to an inappropriate or ineffective immune
response to pathogen challenge. Indeed, in general the
links between the immune and neurological systems are
becoming increasingly well known. Products of the
immune system may play an important role in early
neurodevelopment and can inﬂuence patterns of behavior.
The immune and nervous system are both complex, highly
evolved systems preserved within structural networks that
transfer signals through the release of chemical mediators
such as neuropeptides and cytokines. In addition, the
neuronal synapse and the contact interface between T cells
and antigen presenting cells share a structurally similar
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between the immune and nervous systems, with many
peptides playing a role in both. In ASD, through the
analysis of neuropeptide and neurotransmitter levels,
many neuroactive compounds that also share immuno-
modulatory properties, have been implicated in the disease
process.
NEUROTRANSMITTERS AND
NEUROIMMUNOLOGY
Neuropathologic ﬁndings in autism include reduced
numbers of neurons and reduced dendritic arborisation
in the amygdala, hippocampus, mammillary bodies and
medial septial nucleus (Kemper and Bauman, 2002). In
addition, observations of increased brain size compared
with controls and decreased numbers of Purkinje and
granule cells have also been noted in autism (Volkmar
et al., 2003). These ﬁndings clearly indicate that there are
neurological involvements in ASD that affect the
development and differentiation of neurons in the brain.
It has been proposed that increased or abnormal levels of
neuroactive compounds early during neurodevelopment
may lead to autism. Indeed, abnormalities in various
neurotransmitter systems have been implicated in the
development of autism, including serotonin, dopamine,
noradrenaline (norepinephrine), gamma-aminobutryic
acid (GABA), glutamate and neuropeptides. Such
peptides as oxytocin and vasopressin which are involved
in immune tolerance, serotonin (5-HT) which exerts
concentration dependent suppressive or proliferative
responses on T cells, and the immunomodulating
vasoactive intestinal peptide (VIP), have all been
implicated in ASD (Nelson et al., 2001; Sharp, 2003).
Serotonin is a biogenic amine that has wideranging
effects on numerous physiological processes such as
circadian rhythyms, appetite, mood, sleep, anxiety, motor
activity and cognition. Serotonin is found in serotonergic
neurons of the nervous system, enterochromafﬁn and
neuroendocrine cells of the endocrine system as well as in
platelets and on lymphocytes of the immune system.
Consistent ﬁndings of increased peripheral blood platelet
serotonin levels have been demonstrated in approximately
one third of children with autism (Anderson et al., 1990;
Singh et al., 1997), while selective 5-HT reuptake
inhibitors have been shown to be beneﬁcial with regard
to treating obsessional and repetitive behavioral pheno-
types in some patients (McDougle et al., 1996). The
mechanism by which platelet 5-HT is elevated remains
unknown, but it is likely that the effect is due to alterations
in the platelets themselves resulting in increased platelet
uptake or reduced platelet 5-HT2 receptor binding
(Cook and Leventhal, 1996). Interestingly, auto-anti-
bodies directed toward serotonin receptors have been
found in autistic patients compared with controls (Todd
and Ciaranello, 1985; Singh et al., 1997), suggesting
an abnormal immune response may be involved in
serotonin regulation. In addition, enzymes that control
the conversion of tryptophan into serotonin or the
formation of kynurenine derivatives are under the control
of cytokines such as IFNg and IL-1 (Dunn et al., 1999;
Wirleitner et al., 2003). Typtophan depletion has
previously been shown to result in an increase of autistic
behaviors (McDougle et al., 1996). Thus, accelerated
tryptophan degradation as a result of immune activation
could lead to an increase in autistic features. In autistic
boys, decreased measurements of serotonin synthesis in
the frontal cortex and thalamus, but elevated synthesis in
the contralateral dentate nucleus were observed using PET
scans (Chugani et al., 1999). However, factors such as the
age or gender of the subject and associated mental
retardation may alter serotonin levels. Nonetheless it has
been proposed that there exists a normal developmental
process characterized by high serotonin levels in typically
developing children up to 5 years of age, which is
disrupted in autistic children (Chugani et al., 1999).
Encouraging preliminary data have suggested a link
between the 5-HT transporter gene and autism, but so far
the nature of the speciﬁc link remains elusive (Anderson
et al., 2002; Conroy et al., 2004; Nabi et al., 2004).
Similarly, changes in blood levels of norephinephrine,
aspartic acid, glutamine, glutamic acid and GABA have
been shown in individuals with autism compared with
controls (Cook et al., 1990; Rolf et al., 1993), however,
further large scale studies with patients matched for age
and behavioral characteristics need to be performed.
Opioid peptides and opioid receptors are important
modulators of neural development, inﬂuencing migration,
proliferation and differentiation within the CNS (Zagon,
1987). It has been hypothesized that an excess of opioid
peptides will have detrimental effects on brain develop-
ment and behavior, and that autism may be a result of
abnormal levels or activity of opioid peptides. Not only are
immune cells capable of producing opioid peptides, but
they also have opioid receptors on their cell surface. The
precise mechanisms that underlie the immunosuppressive
effects of opioids remain unknown, however, it has been
proposed that they can operate as cytokines (Peterson
et al., 1998), acting through receptors on peripheral blood
and/or glial cells. For example, the anti-inﬂammatory
kappa-opioid drugs are able to reduce adhesion molecule
expression, inhibit cellular trafﬁcking, reduce TNF-a
release and expression, and alter mRNA expression of
neuropeptides, presumably through opioid–receptor
interactions involved in different phases of an immune
response (Walker, 2003). In contrast, beta-endorphin
increases the expression of complement and Fcg receptors
on the surface of neutrophils and induces concentration
dependent stimulation of reactive oxygen intermediates
(Menzebach et al., 2003). The actions of beta-endorphin
on neutrophils are mediated through the N-terminal
fragment, and not the C-terminal fragment. Studies on
beta-endorphin in autism have found increased C-terminal
and reduced N-terminal beta-endorphin fragments
(Leboyer et al., 1994). However, a clear pattern of beta
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studies have found increased, decreased and normal levels
in plasma and CSF (Croonenburghs et al., 2002). Another
important source of opioids with neurmodulating activity
is from the diet. Beta-casemorphine-7, an opioid
exclusively of dietary origin, has been shown to be
present in patients with pyschoses including autism
(Wakeﬁeld et al., 2002). Indeed, the beneﬁcial effects on
autistic behavior following dietary exclusion therapy are
thought, in part, to be a result of reduced opioid intake
(Knivsberg et al., 1995; Whitely et al., 1999; Knivsberg
et al., 2002). Furthermore, therapeutic trials using the oral
opioid antagonist, naltrexone, in autism have shown
improvements in behavioral characteristics such as
repetitive stereotypies, social contact, and self-injury
(Herman et al., 1987; Panksepp et al., 1991; Zingarelli
et al., 1992). How the immune system is affected by these
therapeutic interventions is largely still unknown.
Neuropeptides are small, biologically active peptides
derived from the central and peripheral nervous system.
Through animal models, it has been suggested that the
neuropeptides oxytocin and vasopressin play a critical role
in the regulation of social recognition, afﬁliation and
attachment (Young et al., 2002). Prairie voles are social
animals who form long lasting pair bonds. Central
infusion of oxytocin in females or vasopressin in males
helps to establish partner bonding, a phenomenon that can
be blocked using speciﬁc antagonists (Williams et al.,
1994; Young et al., 2001). In prairie voles, oxytocin and
vasopressin receptors are located in the ventral forebrain
whereas, in contrast, asocial or solitary montane voles
which do not form bond pairs have different patterns of
expression for oxytocin receptors (Young et al., 2002).
Therefore, the pattern of receptor distribution together
with the concentration of released neuropeptides are
important in the establishment of socially rewarding
interactions. Furthermore, oxytocin knockout mice have
normal cognitive abilities but have diminished social
recognition (Ferguson et al., 2000). In autism, plasma
levels of oxytocin are reported to be signiﬁcantly lower
than controls (Modahl et al., 1998). In addition, further
analysis of neuropeptides in neonatal blood by recycling
immunoafﬁnity chromatography found that concen-
trations of VIP, calcitonin-gene related peptide, brain-
derived neuurotrophic factor and neurotrophin 4/5 were
increased in ASD compared with typically developing
control children but could not be distinguished from those
with mental retardation (Nelson et al., 2001). So far,
signature patterns of neurpeptides and neurotransmitters
in autism have yet to be established.
It is increasingly clear that besides their function as
neurotransmitters, neuropeptides have an inﬂuence on
almost all body functions including the immune system.
For example, oxytocin is present in the thymus at high
levels and is expressed on thymic epithelial cells, where it
is thought to act both as a self-antigen and as a promoter of
T cell focal adhesion (Gimpi and Fahrenholz, 2001) and as
such plays a role in immune tolerance. In addition,
Dunzendorfer et al. have suggested a role for neuropep-
tides as immunomodulators and have presented a novel
concept of neuropeptide-mediated regulation of dendritic
cell (DC) migration. They investigated locomotion of
mononuclear cell-derived DCs at different maturation
stages toward gradients of sensory neuropeptides in vitro.
Calcitonin gene-related peptide, VIP, secretin, and
secretoneurin induced immature DC chemotaxis com-
parable to the potency of the chemokine RANTES,
whereas substance P and macrophage-inﬂammatory
protein-3 beta stimulated immature cell migration only
slightly. Moreover, there was a distinct neuropeptide-
induced signal transduction seen in DC exposed to
neuropeptides (Dunzendorfer et al., 2000). In addition, it
has been shown that VIP synergizes with TNF-a in
the induction of DC maturation (Delneste et al., 1999).
The notion that a defect in DC chemotaxis could have
ramiﬁcations on the normal process of immature DC
migration to sensory nerve ﬁbers where they participate in
inﬂammatory events is intriguing in the context of autism.
In the central nervous system (CNS) DCs have been found
in normal meninges, the choroid plexus, and cerebrospinal
ﬂuid. During inﬂammation in the CNS, there is a
recruitment of DCs. It has been speculated that they may
equally play a role in the defense against infections and
contribute to the break-down of tolerance to CNS
autoantigens (Pashenkov et al., 2003). Microglia cells,
another CNS cell lineage, are antigen presenting cells
(APCs) that share similarities with both DCs and
macrophages. Microglia cells, as part of the CNS innate
immune system, participate in many reactive processes in
the CNS and have been implicated in the exacerbation of
neurological conditions such as multiple sclerosis,
Alzheimer’s disease, AIDS, and viral encephalitis
(Nelson et al., 2002). In the autoimmune encephalo-
myelitis (EAE) model and in patients with multiple
sclerosis, self-myelin antigens were observed in cells
expressing DC/macrophage markers, MHC class II, and
co-stimulatory molecules, a ﬁnding not present in controls
(de Vos et al., 2002). Taken together, these ﬁndings
suggest a central role for DC and neuropeptide mediated
chemotaxis in the control of CNS inﬂammation and
modulation of T cell reactivity against CNS antigens.
Cytokines and other products of immune activation
have widespread effects on neuronal pathways, and in part
may be responsible for many common features of ASD
such as mood and sleep disturbances. The brain is
protected and isolated by the blood brain barrier from
potentially deleterious agents present in the blood
including inﬂammatory immune cells and proteins.
However, recent data have suggested that the brain is an
immunologically active organ and that immune reactions
do occur within the CNS. The entry of cytokines produced
in the periphery into the brain is predominantly restricted
by the blood brain barrier. However, they may gain access
through active transport mechanisms or at circumven-
tricular regions where the barrier is less controlling
(Wilson et al., 2002). In addition, cytokines may affect
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brain endothelial cells leading to the impairment of
function (Wilson et al., 2002). Evidence has emerged that
leuckocytes migrate into the brain from the blood via the
cerebral spinal ﬂuid to the choroids plexus, or from the
blood to either the subarachnoid space or parenchymal
perivascular space (Ransohoff et al., 2003). These
leuckocytes may then act as a potential source of
cytokines. Alternatively, afferent neurons may be directly
responsive to peripheral cytokine stimulation (Dantzer
et al., 1998). Indeed, cytokines can affect enteric glial
cells (Von Boyen et al., 2004). The effects of cytokines on
the mood, sleep, nutritional intake, exploratory behavior,
and social interactions do not necessarily have to result in
neuronal damage or death. Systemic cytokines adminis-
tered at therapeutic doses, such as IFN-a, IL-2 and
TNF-a, have side effects including mood depression,
sleep disorder, impaired cognitive function, decreased
exploratory behavior, and changes in motivation (Licinio
et al., 1998; Larson, 2002). Systemic cytokine adminis-
tration can also cause increases in noradrenergic,
dopaminergic and serotonergic metabolism in the
hypothalamus, hippocampus and nucleus accumbens
(Mohankumar et al., 1991; Shintani et al., 1993; Merali
et al., 1997). Cytokines can activate and exert trophic
effects on glial cells, and in turn, glial cells can produce
cytokines and chemokines upon activation. As the CNS is
largely populated by astroglia and microglial cells, these
cytokine–cell interactions have important implications for
neuronal cell functioning and development.
SYSTEMIC IMMUNE ABNORMALITIES
IN ASD PATIENTS
Various immune abnormalities have been described by an
increasing number of laboratories worldwidewith ﬁndings
consistently showing both the involvement of autoimmune
processes and the dysregulation of the immune response in
children with autism. Many autistic children suffer
prolonged and recurrent infections, as well as reduced
responsiveness to common recall antigens on cutaneous
delayed hypersensitivity tests compared with controls
(Murch et al., 1999). Immune aberrations consistent with
a dysregulated immune response reported in ASD children
include decreased peripheral lymphocyte numbers
(Ashwood et al., 2003), decreased response to T cell
mitogens (Stubbs and Crawford, 1977; Warren et al.,
1986), incomplete or partial T cell activation evinced by
increased numbers of DRþT cells without the expression
of the IL-2 receptor (Plioplys et al., 1994; Denney et al.,
1996), dysregulated apoptosis mechanisms (Engstrom
et al., 2003), and the imbalance of serum immunoglobulin
levels including increased IgE and decreased serum IgA
(Ashwood et al., 2003). In initial cytokine analysis studies
of 10 autistic children Stubbs (Stubbs, 1995) showed
increased levels of plasma IFN-a compared with 4 adult
controls. In a further study, plasma levels of IL-12 and
IFNg were increased in autistic children but there were no
differences between IL-6, TNFa and IFNa when
compared with controls (Singh, 1996). These studies
proposed that there are aberrant T cell cytokines proﬁles in
children with ASD compared with controls. However,
there is an apparent divergence of opinion on the
predominant polarity of the dysregulated immune
response. In cell culture studies, Gupta showed intra-
cellular cytokine levels of stimulated IL-2 and IFNg
expressing CD4þ and CD8þ cells to be lower in 20
autistic patients compared with 20 aged matched controls.
In contrast, the number of CD4þ and CD8þ cells
expressing IL-4 were increased (Gupta et al., 1998).
Croonenburghs et al. (2002) reported increased IFNg,
IL-6 and IL-1ra in unstimulated culture supernatants from
ASD patients, although no information on experimental
design or details of autistic patients or controls were given.
More recently, plasma IFNg levels in 29 autistic children
correlated positively with the generation of the potent
functional and developmental intercellular CNS messen-
ger nitric oxide (NO), a ﬁnding indicative of NO-related
oxidative stress (Sweeten et al., 2004). A similar
mechanism of IFNg induced plasma neopterin, may be
responsible for the elevated levels observed in autistic
patients and may reﬂect cell-mediated immune activation
(Sweeten et al., 2003). Evidence for an increased
inappropriate innate immune response was shown by the
over-production of pro-inﬂammatory cytokines, in par-
ticular TNFa, in peripheral blood mononuclear cells
stimulated with bacterial LPS in ASD children compared
with controls (Jyonouchi et al., 2001). Interestingly,
siblings also showed raised TNFa levels compared with
controls suggesting a genetic defect in control of innate
immune responses in children with ASD and their family
members. Furthermore, decreased NK cell activity has
been shown in ASD children and is further indicative of a
functional deﬁcit in the innate immune response (Warren
et al., 1987). However, very few studies on the innate
system in patients with autism have been performed thus
far. Other ﬁndings in autistic subjects, with an
immunological signiﬁcance, include increased frequency
of the null alleles of complement and HLA-DRB1*04
allele and low levels of C4b complement protein (Warren
et al., 1991, 1994, 1996). However, it is hard to ascertain a
clear signature immune cellular or cytokine response in
the pathology of early childhood development seen in
autism. So far there are a lack of systematic studies with
sufﬁciently large enough sample sizes. In addition, many
studies are not adequately matched for the age and gender
of subjects and controls, where autistic children are often
compared with much older controls. In part, these
difﬁculties occur as there is often limited access to
autistic populations and the behavioral aspects of autism
make sampling difﬁcult. Furthermore, the young age of
the subjects makes rigorous and wide-ranging immuno-
logical studies prohibitive. A further consideration is that
it is now becoming increasingly apparent that autistic
patients may be categorized into various phenotypes based
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behavioral aspects. In the future, well deﬁned studies
with fully characterized patient and matched control
groups will need to be performed in order to ascertain how
the immune response is involved in autistic pathology.
AUTOIMMUNE PROCESS IN ASD
The presence of antibodies directed against components
of the CNS in the sera of autistic children, is indicative
that a possible autoimmune process may be involved in
the pathology of ASD. Autoimmune diseases arise when
the immune system is inappropriately directed to
recognize and exert an exaggerated respond to “self”
components. These include, but are not restricted to
diseases such as; myasthenia gravis, multiple sclerosis,
systemic lupus erythematosus, primary biliary cirrhosis,
and Graves thryrotoxicosis. The exact mechanism of
autoimmunity in these diseases is not identical, but they
all possess autoreactive antibodies and T cells. Various
anti-brain antibodies have been found in autistic patients
including autoantibodies to serotonin receptor (Todd and
Ciaranello, 1985), myelin basic protein (MBP) (Singh
et al., 1993), neuron axon ﬁlament protein (NAFP) (Singh
et al., 1997), cerebellar neuroﬁlaments (Plioplys et al.,
1994), nerve growth factor (Kozlovskaia et al., 2000),
alpha-2-adrenergic binding sites (Cook et al., 1993), anti-
brain endothelial cell proteins (Todd et al.,1 9 8 8 ;
Connolly et al., 1999) and antibodies against the caudate
nucleus (Singh and Rivas, 2004). In a recent paper, serum
from a mother with an autistic child found to bind to
Purkinje cells and other neurons, when injected into
gestating mice, induced behavioral changes including
altered exploration, motor coordination and changes in
cerebrallar magnetic resonance spectroscopy in the
offspring. In contrast, mice injected with sera from
mothers with typically developing children showed no
behavioral changes (Dalton et al., 2003). This study
supports the notion that maternal antibodies may
inﬂuence the neurodevelopmental process in autism.
In addition, the frequency of autoimmune disorders in
family members of 61 ASD children and 46 typically
developing normal controls were compared (Comi et al.,
1999). The frequency of autoimmune disorders was
increased in the ASD group with over 40% of families
having two or more close family members with
autoimmunity. Findings that have since been replicated
by Sweeten et al. (2003) in families of pervasive
developmental disorder probands. However, these studies
were based on self-reporting rather than medical
records and thus may have a signiﬁcant margin of
reporting error.
The pathophysiological signiﬁcance of auto antibodies
reported in children with autism is uncertain. For example
increased autoantibodies would suggest that there is
increased neuronal damage, as is the case in multiple
sclerosis where, following demyelination, MBP is
unmasked and there is a subsequent generation of
antibodies. To date however, evidence of demyelination
in autism has remained elusive (Rumsey and Ernst, 2000).
Glial ﬁbrillary acidic protein (GFAP) measured in the CSF
of 47 autistic children was signiﬁcantly elevated compared
to age matched 10 control children, suggesting that gliosis
and unspeciﬁc brain damage may occur in autism (Ahlsen
et al., 1993). However, as GFAP correlates strongly with
age, due most likely to age dependent expansion of
ﬁbrillary astrocytes, caution must be shown in interpreting
these data (Rosengren et al., 1992). Another possible
cause for the development of autoimmunity is a
dysfunction in immune regulation, that allows immune
responses to continue unchecked. One regulatory T cell
population is identiﬁed by the combination of the CD4
(T helper cells) and CD25 (IL-2 receptor) cell surface
markers, which are a cell population that as discussed
above, is at a low frequency in autism. A dysregulation
of IL-10 and TGFb1 release parallel to times when
pro-inﬂammatory signals such as TNFa are high, will lead
to an imbalance of inﬂammatory signals. Furthermore,
defects in apoptosis mechanisms will promote the survival
of immune cells including autoreactive lymphocytes.
Dysregulated FAS mediated cell death and increased
soluble FAS receptor have been described in autism
(Engstrom et al., 2003). Observations of elevated
anti-CNS antibodies in autism, are at best unconﬁrmed,
and in some cases, for example serotonin receptors and
MBP, markedly conﬂicting. However, taken together the
ﬁndings of autoimmunity in families and the plethora of
anti-brain antibodies suggest that in some patients,
autoantibodies that target the CNS may be a pathological
or exacerbating factor in neuronal development in
children with ASD. It is also important to note that for
each antibody tested the number of autistic children
showing positivity was far from 100%. It is also unclear
whether individual autistic children are positive for more
than one antibody. Again, it can be inferred that increased
autoimmunity may be conﬁned to a subset of autistic
patients. Indeed, large cohort studies with thoroughly
deﬁned and speciﬁcally phenotyped autistic patient groups
and well matched age and sex controls, need to be
performed to conﬁrm the potential role of autoantibodies
in the pathology of either all or subsets of autistic patients.
Moreover, the development of an animal model will be
crucial to determine the role of autoantibodies in the
pathology of autism.
RESPONSE TO VIRUSES
Many infectious agents including; rubella, measles,
human herpesvirus 6 (HHV-6), inﬂuenza and cytomega-
lovirus have been associated with the aetiology of autism
(Chess et al., 1978; Binstock, 2001; Yamashita et al.,
2003). These associations, although not conclusive for all
children with ASD, may highlight an underlying inability
of ASD children to fully eradicate viral insults. As such,
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ASD. Indeed, defects in T cell numbers and function, a
phenomenon observed in ASD, may compromise the
body’s defense system to infectious agents and engender
the body susceptible to recurrent infections. Persistent
viral infection has been described in mucosal tissue of
ASD children compared with age-matched typically
developing controls, with viral RNA present in DC
populations (Uhlmann et al., 2002). This persistence may
be indicative of a primary failure to successfully eradicate
antigen and the inability to deal with viral insults.
Furthermore, increases in lymphoid tissue seen at mucosal
sites in ASD children may be reﬂective of a local
inﬂammatory response to the presence of a persisting Ag
(Wakeﬁeld et al., 2000; Ashwood et al., 2003).
Paramyxoviruses, such as measles have profound effects
on DC function including the inhibition of LPS stimulated
IL-12 release. In addition, the ability to stimulate T cell
proliferation by mitogen, was greatly reduced in the
presence of measles infected DCs (Klagge and Scheider-
Schaulies, 1999). The migration of infected DCs to T cell
areas of lymphoid organs could therefore exert immuno-
suppressive effects on the surrounding T cells.
In a mouse model, viral infections in pregnant mothers
leave long-lasting effects on the offspring, including an
increased risk of behavioral abnormalities with particular
relevance to autism and schizophrenia (Patterson, 2002).
In pregnant mice (BALB/c and C57BL/6 strains), when
human inﬂuenza virus was administered, offspring
displayed aberrant behavioral responses as adults, with
deﬁcits in prepulse inhibition (PPI) in the acoustic startle
response, ﬁndings also observed in autistic subjects
(Fatemi et al., 2002). It is hypothesized that maternal
immune responses generated to eradicate the viral insult
affect fetal brain development and the upregulation of
speciﬁc cytokines are implicated at this time. In another
animal model, infection with Borna disease virus (BDV)
in Lewis rats leads to behavioral and CNS abnormalities
reticent of neurodevelopmental disorders such as schizo-
phrenia and autism in humans (Hornig et al., 1999). Borna
disease virus infection primarily targets the hippocampal
neurons, affecting ERK 1/2 phosphorylation, the
expression of synaptic vesicle proteins, and hampers
synaptogenesis and synaptic organization induced by the
neurotrophin brain-derived neurotrophic factor (BDNF).
However, BDNF receptor expression, neuronal survival
and morphology are not affected (Hans et al., 2004).
These ﬁndings show that BDV acts in a non-cytopathic
way to alter neuronal growth factor mediated events and
thereby alter synaptic connections between neurons,
possibly by interfering with cell signaling events down-
stream of receptor binding, where such alterations may
affect all functions of the brain. These models of infection
will provide valuable insight into the mechanisms of
human neurodevelopmental disorders and the interplay of
the developing neuronal and immune system in the
pathology of environmentally induced behavioral
abnormalities.
Bacterial and viral infections have been suspected in the
triggering of or excacerbation of autoimmune diseases
(Panoutsakopoulou and Cantor, 2001). In autism, patients
with anti-measles IgG antibodies were also positive for
anti-MBP (90%) and anti-NAFP (73%) antibodies, a
similar relationship were seen in patients with positive
titers for anti-HHV-6 antibodies and corresponding anti
MBP and anti-NAFP antibodies (Singh et al., 1998).
Interestingly, in these studies anti-measles and anti-
HHV-6 antibodies were not different between autistic
patients and controls. The underlying mechanism between
viral insults and disease in autism remains unclear.
Pathogenesis may result due to cellular damage induced as
a result of immune responses aimed at eradicating an
invading virus. Equally, impaired immune responses
could increase susceptibility to infections in autistic
children, or an inability to clear viruses leading to
persistent infections that could then subvert immune
function or act directly upon the CNS to elicit
neurodevelopmental abnormalities. The study of patho-
gen-induced immune responses and the pattern of pre- and
post-natal exposures on the developing neuronal system
may provide interesting data.
MUCOSAL IMMUNITY IN ASD PATIENTS
Gastrointestinal symptoms have been described in a
number of ASD patients, in whom symptoms include
abdominal pain, bloating, diarrhoea and constipation
(Horvath et al., 1999; Afzal et al., 2003). The precise
number of children with ASD who have gastrointestinal
symptoms is not currently known, but some studies have
estimated this to be between 18 and 40% (Baron-Cohen
et al. 1996; 2000; Horvath et al., 1999; Fombonne et al.,
2001). Reported gastrointestinal abnormalities include
low activities of disaccharidase enzymes, defective
sulphation of ingested phenolic amines (paracetamol),
bacterial overgrowth with greater diversity and number of
clostridial species, more numerous Paneth cells, increased
intestinal permeability and a positive effects on behavioral
cognition following dietary intervention (Knivsberg et al.,
1995; 2002; D’Eufemia et al., 1996; Alberti et al., 1999;
Horvath et al., 1999; Finegold et al., 2002). Clinical and
pathological studies have described an apparently
characteristic gastrointestinal immunopathology in this
subset of ASD children (Wakeﬁeld et al., 1998, 2000;
Furlano et al., 2001; Torrente et al., 2002), in which
chronic ileo-colonic lymphoid nodular hyperplasia (LNH)
and entero-colitis are key features. The mucosal lesion
consists of a pan-enteric lymphocytic inﬁltrate, with a
variable degree of acute inﬂammation and eosinophil
inﬁltration (Wakeﬁeld et al., 1998, 2000; Furlano et al.,
2001; Torrente et al., 2002). Flow cytometric and
immunohistochemical analyses of mucosal lymphocyte
populations in ASD children have demonstrated qualita-
tively consistent abnormalities at different anatomical
sites including stomach, duodenum, ileum and colon
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2003), indicating a relatively homogenous mucosal
lymphocyte inﬁltrate. Although LNH is not an uncommon
ﬁnding in children with allergies or immunodeﬁciency,
there is increased frequency and severity in patients with
autism (Wakeﬁeld et al., 2002). In addition, ﬁndings of
focal deposition of serum IgG from ASD children which
co-localises with complement C1q on the basolateral
enterocyte membrane, changes not seen in histologically
normal and inﬂamed mucosa of developmentally normal
children or children with cerebral palsy (Torrente et al.,
2002), and increased intestinal permeability in ASD
(D’Eufemia et al., 1996) is suggestive of an inﬂammatory
process that may perturb the intestinal barrier function in
ASD children. Co-localisation of immunoglobulin and
complement components on the epithelial membrane have
been found in both stomach and duodenal specimens and
may be indicative of an autoimmune process directed
against self-antigen contained within epithelial cells
(Torrente et al., 2002). Furthermore, increased basement
membrane thickness and abnormal patterns of epithelial
glycosaminoglycans have been seen in autistic children
compared with controls and may be indicative of
inﬂammatory degradation that could contribute to
disruption of the intestinal barrier function (Furlano
et al., 2001).
While there is a great deal of speculation, the exact
mechanism of how mucosal changes may inﬂuence
autistic development or behavior is still not clear. It may
be that antigens in the diet can cross the mucosa more
easily through the disrupted intestinal barrier, where they
cause local inﬂammatory reactions generating pro-
inﬂammatory cytokine signals that interact with afferent
neurons. Another possibility is that the failure to detoxify
neuroactive antigens from the gut may lead to cognitive
impairments. Similarly, increased passage of exorphins
and/or opioids from the diet such as gliadomorphin and
casomorphin into the body, where they can interact
directly with the CNS, may play a role in inducing
behavioral features of autism. In a further theory, reduced
ileal absorption of vitamin B12, a necessary cofactor for
nerve myelogenesis and the formation of myelin
(Wakeﬁeld et al., 1998; Cornish, 2002), could lead to
impaired nerve function, which again highlights how
altered mucosal integrity may induce neuronal and
behavioral changes. However, conclusive evidence to
answer how disrupted intestinal mucosal functions affect
neurodevelopment and the CNS is still necessary.
In peripheral blood, elevated pro-inﬂammatory
cytokines have been reported to be produced upon
stimulation with dietary proteins in autistic children
compared with controls (Jyonouchi et al., 2001). In some
studies, circulating antibodies to food substances, namely
casein and gliadin have been found (Reichelt et al., 1990;
Lucarelli et al., 1995). However, these antibodies are also
found with similar frequency in typically developing
population. Furthermore, antibodies to neuronal speciﬁc
antigens in the sera of children with autism could cross
react with dietary peptides including milk butyrophilin,
streptococcus M protein and chlamydia pneumoniae
(Vojdani et al., 2002), suggesting that bacterial infections
and milk antigens may modulate the autoimmune process
in autism. Interestingly, mucosal lymphocytes isolated
from the duodenum, ileum and colon of ASD
patients showed increased spontaneous production of
pro-inﬂammatory intracellular cytokines, most notably
TNFa, when compared with aged matched controls,
including those with similar symptoms of constipation
(Ashwood et al., 2002, 2003). In addition, of particular
interest was the inverse relationship between raised
numbers of pro-inﬂammatory TNFa positive lymphocytes
and decreased numbers of cells expressing the regulatory
cytokine IL-10 in ASD children. These ﬁndings support
the hypothesis that there is mucosal immune dysregulation
with a pro-inﬂammatory lymphocyte cytokine proﬁle, in
ASD children. However, in a study that included one
autistic child and two with ASD, macrophage release of
monokines including IL-1b from ex vivo biopsy explant
cultures into culture supernatant was not statistically
different when compared with nine older children
(Defelice et al., 2003). These data may indicate
differential roles for activated lymphocytes and antigen
presenting cells in the entero-colitis associated with some
autistic children. In an open-label trial, administration of
vancomycin, an antibiotic that is poorly absorbed, resulted
in objective cognitive improvements in autistic children
(Sandler et al., 2000), presumably due to treatment of
intestinal dysbiosis. However, once administration of
vancomycin was ceased, the patients cognitive functions
regressed suggesting that the initial improvement was
through beneﬁcial effects on the intestinal pathology
(Wakeﬁeld et al., 2002). The exacerbation of gastrointes-
tinal and behavioral symptoms in autism induced by
certain foods, particularly those containing gluten and
casein, has been shown through dietary intervention and
their removal from the diet (Knivsberg et al., 1995, 2002).
Autistic children on gluten and casein free diets also
showed signiﬁcantly lower eosinophil inﬁltrate in
intestinal biopsies compared with those on a conventional
diet (Ashwood et al., 2003). The signiﬁcance of this
ﬁnding is still unclear. However, it has been recently
proposed that immune responses associated with allergy
may contribute to the pathogenesis of autoimmune
diseases of the CNS in both humans and in animal models
(Pedotti et al., 2003).
IMMUNE THERAPY
Various studies have demonstrated that immunotherapy
may be effective in the treatment of some children with
autism (Gupta et al., 1996; Plioplys, 1998; Gupta, 2000;
Wank, 2002). As stated above, studies that have shown
cognitive beneﬁt from dietary intervention have been
based upon the assumed removal of substrates for
certain neuroactive opioid peptides present in the food
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exclusively, food antigens may provide a pro-inﬂamma-
tory stimulus in some ASD children, as suggested by the
data of Jyonouchi et al. (2001). Additionally, alterations
in gut ﬂora induced by dietary changes or by the
administration of antibiotics may lead to beneﬁcial
effects. Further studies on immune based therapies
including the administration of transfer factor, treatment
with pentoxifylline, and intravenous immune globulin
treatment have shown improvements in some autistic
children (Gupta, 2000). However, these studies remain to
be conﬁrmed in larger placebo controlled, double-blinded,
crossover studies with well matched control and subject
groups. Furthermore, in depth behavioral assessments
before and after treatment need to be performed.
CONCLUSIONS
While there is a growing cognizance of immunological
dysfunction in some ASD children, a great deal of
research remains to be done. There are several aspects of
the immune phenomenology thus far reported in ASD that
require further investigation. Among these is the
suggestion that patients with ASD have an altered or
inappropriate response to viruses, the nature, extent and
involvement of autoimmune processes in disease, and the
importance of mucosal inﬂammation co-morbidity in
some children. Each of these potentially pathological
processes may be involved in the aetiology of autism in
only a subset of children, or to varying degrees in all.
Among the current and highly controversial data, there is
much speculation, but little is truly known about the
response of children with ASD to foreign antigens. The
link between the immune and neurological systems is
becoming increasingly well known. Products of the
immune system play an important role in early
neurodevelopment and can inﬂuence patterns of behavior.
Bidirectional communication between the immune and
nervous systems with many neuropeptides and neuro-
transmitters playing a role in both, is also of great interest.
How the various immune abnormalities that have been
reported in patients with ASD, are related to the
development of neurologic changes is not yet known. In
addition, exposure of the developing neuronal system to
enhanced or aberrant immune responses during critical
periods of development may not be uniform and may lead
to the expression of different phenotypes in autistic
patients, dependent upon rates of neuronal and immune
development and genetic composition. So far, no clear
signature patterns of cellular or cytokine responses have
been found in autistic patients that can identify autism
from other neurodevelopmental disorders, nor identify
immunological ﬁndings to speciﬁc behavioral symptoms
such as clinical behavioral regression. Large cohort
studies on well deﬁned patient and aged matched control
groups will be needed to unravel the importance of the
immune system in autism.
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